PF4 and systemic sclerosis: Despite the fact that we have not observed differences in anti-CXCL4-autoantibody reactivity in SSc-progressors versus non-progressors, it is still possible that the autoantibody specificity and effector functions evolve in a different manner in SSc-progressors versus non-progressors at a given time point.